Compare FSUN & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | ANAB |
|---|---|---|
| Founded | 1892 | 2005 |
| Country | United States | United States |
| Employees | 1186 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | N/A | 2015 |
| Metric | FSUN | ANAB |
|---|---|---|
| Price | $35.52 | $55.70 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $45.00 | ★ $71.67 |
| AVG Volume (30 Days) | 141.0K | ★ 501.3K |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $234,603,000.00 |
| Revenue This Year | $79.34 | N/A |
| Revenue Next Year | $14.67 | $52.14 |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $29.95 | $17.11 |
| 52 Week High | $42.34 | $73.30 |
| Indicator | FSUN | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 37.43 |
| Support Level | $34.44 | $53.46 |
| Resistance Level | $37.12 | $57.70 |
| Average True Range (ATR) | 0.87 | 3.58 |
| MACD | 0.03 | -0.90 |
| Stochastic Oscillator | 38.49 | 5.35 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).